Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Via News Knowledge File

AbbVie Inc.

organization80% conf.·synced Aug 13, 2026

Biopharmaceutical company based in North Chicago, Illinois, developing oncology and hematology therapeutics

48
sourced metrics
521
relationships
20
stated objectives
3
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
248.76USD
Aug 12, 2026reference only
Price 52 Week High
263.30USD
Aug 12, 2026reference only
Stock Return Ytd
8.5%
Aug 12, 2026reference only
Price 52 Week Low
197.38USD
Aug 12, 2026reference only
Net Income
3613000000.0USD
Jun 30, 2026reference only
Capex
587000000.0USD
Jun 30, 2026reference only
Cash
6569000000.0USD
Jun 30, 2026reference only
Stockholders Equity
-5935000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
4291000000.0USD
Jun 30, 2026reference only
Total Assets
135115000000.0USD
Jun 30, 2026reference only
Revenue
16990000000.0USD
Jun 30, 2026reference only
Eps
2.03USD_per_share
Jun 30, 2026reference only
Operating Income
6432000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
7265000000.0USD
Jun 30, 2026reference only
Consecutive Dividend Increases
53years
May 25, 2026source
Mid Late Stage Clinical Trials
60programs
May 25, 2026source
Pipeline Total Programs
90programs
May 25, 2026source
Portfolio Weight In Xlv
7.09percent
May 18, 2026source

Stated objectives

Develop and commercialize 35+ investigational medicines in multiple clinical trials across hematologic cancers

source
target: 35 stated

Pursue additional international regulatory approvals for the R/R FL indication

source
stated

Evaluate epcoritamab as monotherapy and in combination across lines of therapy in a range of hematologic malignancies through four ongoing Phase 3 trials

source
stated

Achieve adjusted diluted EPS for 2025

source
target: 12.12 to 12.32 USD by 2025-12-31 00:00:00stated

Achieve high single-digit compound annual revenue growth rate for ex-Humira platform

source
target: high single-digit percent by 2029-12-31 00:00:00stated

Achieve combined sales of immunology duo

source
target: 27 billion USD by 2027-12-31 00:00:00stated

Raised full-year earnings guidance

source
target: $10.61-$10.65 EPS by 2025-12-31 00:00:00stated

High single-digit CAGR through 2029

source
target: high single-digit percent CAGR by 2029-01-01 00:00:00stated

Drive long-term growth through early-stage pipeline development

source
stated

Return to robust revenue growth following Humira LOE

source
by 2025-01-01 00:00:00stated

Relationship graph · 521 connections

Developed by
245
Competes with
48
Covered by
41
headquartered in
30
Employs
27
regulates
18
acquired by
12
Invested in
10

Via News coverage

FDA PDUFA Wave in 2026 Sets Up Binary Catalyst Season Across ADC, Cell Therapy, and Checkpoint Inhibitor Portfolios
June 19, 2026
REGENXBIO Eyes 2027 Commercial Launch for Duchenne Gene Therapy as Pivotal Trial Wraps Enrollment
February 18, 2026
Jade Biosciences Eyes Phase 1 Launch for JADE301 as Autoimmune Pipeline Takes Shape
February 18, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com